Bulletin
of the Multinational Center
of Quality of Life Research № 13-14

T.I. Ionova, D.A. Fedorenko, N.E. Mochkin, K.A. Kurbatova, A.A. Novik.

Patient-reported outcomes in patients with multiple sclerosis undergoing autologous hematopoietic stem cell transplantation

Patient-reported outcomes in patients with multiple sclerosis after autologous hematopoietic stem cell transplantation (ASCT) are presented. ASCT in multiple sclerosis patients improves their physical, psychological and social functioning. The most definite improvement of quality of life takes place in a year after transplantation.

After ASCT the number of patients with no QoL impairment increases whereas the number of patients with critical QoL impairment decreases. Quality of life treatment response (QoL improvement or QoL stabilization) was achieved in the vast majority of MS patients after ASCT. ASCT is associated with decline of symptom prevalence and severity in MS patients.